Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous intravenous heparin in acute coronary syndrome
IRCT20170822035849N4Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Sep 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of heparin in acute coronary syndrome (ACS) (2 arms), sponsored by Sabzevar University of Medical Sciences. Primary endpoints: Activated partial thromboplastin time and Heparin-related adverse effects. Started Sep 2017; status: completed.
02
Drugs
heparin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20170822035849N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170822035849N4.